China is one of the largest generic drug markets in the world. As part of the drug approval reform, the ongoing generic consistency evaluation (GCE) is likely to have significant, long-lasting impacts on the market landscape, drug pricing and generic competition. Patent cliff might inevitably follow and should be examined and planned for early.
Please see full publication below for more information.